Results 91 to 100 of about 38,769 (305)

Effect of sodium-glucose Co-transporter 2 inhibitors on MCP-1 and uromodulin levels in patients with type 2 diabetes mellitus

Clinical Epidemiology and Global Health
Background and aim: A class of anti-diabetic medications, namely Sodium Glucose Co-Transporter-2 (SGLT2) inhibitors, has shown their potential effects beyond glucose tolerance in Type 2 Diabetes Mellitus (T2DM) patients.
Mani Pathak, Haya Majid, Parvej Khan, Md Masoom, Rizwana Parveen, Prem Kapur, Sunil Kohli, Nidhi   +7 more
doaj   +1 more source

Update on developments with SGLT2 inhibitors in the management of type 2 diabetes

, 2014
Michael A Nauck Department of Internal Medicine, Diabeteszentrum Bad Lauterberg, Bad Lauterberg im Harz, Germany Abstract: The importance of the kidney's role in glucose homeostasis has gained wider understanding in recent years.
Nauck MA
core  

Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 1176-1182, April 2025.
Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasinglyrecognized cause of heart failure with preserved ejection fraction (HFpEF), which may be diagnosed non‐invasively using 99mTc 3,3‐diphosphono‐1,2‐propanodicarboxylic acid (DPD) scintigraphy‐based diagnostic criteria.
L. Healy, G. Giblin, A. Gray, N. Starr, L. Murphy, D. O'Sullivan, E. Kavanagh, C. Howley, C. Tracey, E. Morrin, A. McDaid, A. Clarke, J.O. O'Neill, E. Joyce, M. O'Connell, N. G. Mahon   +15 more
wiley   +1 more source

The effect of sodium glucose Co-transport 2 inhibitors on cognitive impairment and depression in type 2 diabetes mellitus patients

Clinical Epidemiology and Global Health
Background and aim: Type 2 diabetes mellitus (T2DM) is a prevalent metabolic disorder often associated with thyroid dysfunction. Sodium-glucose co-transport 2 (SGLT2) inhibitors, a novel class of medications for T2DM, have shown potential effects on ...
Ashurova Nodirahon, Haya Majid, Swati Waghdhare, Divya Vohora, Nidhi   +4 more
doaj   +1 more source

SGLT2 inhibitors: Beyond glycemic control

Multiple randomized controlled trials have extensively examined the therapeutic effectiveness of sodium-glucose cotransporter 2 (SGLT2) inhibitors, ushering in a transformative approach to treating individuals with type 2 diabetes mellitus (DM). Notably,
Vishal Jaikaransingh, Emaad M. Abdel-Rahman, Tasnuva Rashid, Alaa S. Awad, Irtiza Hasan, Charles Heilig   +5 more
core   +1 more source

A Fluorescent Glucose Transport Assay for Screening SGLT2 Inhibitors in Endogenous SGLT2-Expressing HK-2 Cells

, 2018
The sodium-dependent glucose transporters 2 (SGLT2) plays important role in renal reabsorption of urinal glucose back to plasma for maintaining glucose homeostasis. The approval of SGLT2 inhibitors for treatment of type 2 diabetes highlights the SGLT2 as
Jing Hu, Wen-Yong Xiong, Yu-Hui Xu, Fang Wang, Yan-Ting Lu, Wan-Ying Qin, Xiu-Li Ma   +6 more
core   +1 more source

eGFR slope as predictor of mortality in heart failure patients

ESC Heart Failure, Volume 12, Issue 2, Page 1217-1226, April 2025.
Abstract Aims Heart failure (HF) leads to an imbalance between heart and kidney function, resulting in poor outcomes. However, the prognostic significance of the estimated glomerular filtration rate (eGFR) trajectory in HF patients remains unclear. We analysed electronic health records (EHRs) of real‐world HF patients, assessing eGFR trajectories and ...
Sofie Verstreken, Monika Beles, Clara L. Oeste, Ana Moya, Imke Masuy, Riet Dierckx, Ward Heggermont, Jeroen Dauw, Dries Hens, Jozef Bartunek, Marc Vanderheyden   +10 more
wiley   +1 more source

Comparative performance of risk prediction indices for mortality or readmission following heart failure hospitalization

ESC Heart Failure, Volume 12, Issue 2, Page 1227-1236, April 2025.
Comparative performance of 7 risk prediction indices in patients hospitalized for heart failure. In this cohort of 1206 patients, the LENT index offered the greatest discrimination, calibration, and overall accuracy in predicting 30‐day composite all‐cause mortality or readmission following hospitalization for heart failure.
Tauben Averbuch, Ali Zafari, Shofiqul Islam, Shun Fu Lee, Rajiv Sankaranarayanan, Stephen J Greene, Mamas A Mamas, Ambarish Pandey, Harriette GC Van Spall   +8 more
wiley   +1 more source

Effects of sodium–glucose co‐transporter inhibitors on individual clinical endpoints and quality of life

ESC Heart Failure, Volume 12, Issue 2, Page 1271-1282, April 2025.
Effects of SGLTi on Individual Clinical Endpoints and Quality‐of‐Life: outcome from randomized data. Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.
Jia Liao, Yang Chen, Zhiyu Ling, Helmut Pürerfellner, Martin Martinek, Michael Derndorfer, Johannes Niel, Ramin Ebrahimi, Matthias Heukäufer, Sarah Janschel, Davide Di Vece, Klaus Empen, Astrid Hummel, Bishwas Chamling, Piotr Futyma, Fahim Ebrahimi, Márcio G. Kiuchi, Shaowen Liu, Yuehui Yin, Alexandra Schratter, Willem‐Jan Acou, Philipp Sommer, Boris Schmidt, Julian K. R. Chun, Christian Meyer, Marcus Dörr, Christian Templin, Shaojie Chen   +27 more
wiley   +1 more source

Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis

Scientific Reports, 2017
Previous trial evidence suggested potential risk of serious urinary tract infections (UTIs) and genital infections in type 2 diabetes patients using sodium glucose co-transporter-2 inhibitors (SGLT2) inhibitors.
Jiali Liu, Ling Li, Sheyu Li, Pengli Jia, Ke Deng, Wenwen Chen, Xin Sun   +6 more
doaj   +1 more source